AI Article Synopsis
- The study highlights a lack of systematic research on the antibody response to Plasmodium falciparum sporozoites, crucial for developing a malaria vaccine.
- In Thailand, antibodies against a specific part of the circumsporozoite (CS) protein were only found in individuals who developed malaria, indicating a link between infection and antibody response.
- The CS antibody response was weak, peaked after parasitemia onset, and did not significantly boost with reinfections, suggesting that these antibodies may not effectively protect against malaria.
Article Abstract
The antibody response to sporozoites of Plasmodium falciparum and the role of these antibodies in protection against malaria have not been systematically investigated. An understanding of antisporozoite antibodies in natural infection is, however, important to the development of a human malaria vaccine. In a prospective study in Thailand, an antibody response to sporozoites was observed only in individuals who developed parasitemia. Antibodies were detected against an epitope in the repeat region of the circumsporozoite (CS) protein. Current candidate sporozoite vaccines are based on CS repeat antigens. The CS antibody response was of low magnitude, peaked after detection of parasitemia, and had a serum half-life of less than 1 month. CS antibody boosting occurred in only 6% of reinfected individuals. These observations suggest that antisporozoite antibody is poorly developed under natural conditions and appears not to protect against development of malaria.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC266487 | PMC |
| http://dx.doi.org/10.1128/jcm.26.5.923-927.1988 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!